Blog | InSphero
March 13, 2020

InSphero launches new webinar series, starting with virtual SOT 2020 sessions

As the coronavirus epidemic prompts cancellations of scientific meetings around the world, we have been working on alternative methods to keep you informed of advances in 3D cell-based assay technology, […]
February 26, 2020

Are I-O therapeutics making traditional in vitro assays obsolete or is it time to reinvent the testing tree?

InSphero Oncology Experts Francesca Chiovaro and Irina Agarkova often collaborate closely with academic and pharma partners who are developing therapeutics that target the innate immune system. In this blog, Francesca shares […]
December 18, 2019

InSphero marks 10 years of Innovation in
3D cell-based assay technology

InSphero CEO Jan Lichtenberg muses about how far 3D cell technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
September 23, 2019

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
July 17, 2019

Can we really find a cure for NASH without the scalability of in vitro NASH models?

InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
July 11, 2019

Developing a multi-tissue platform for advanced embryotoxicity testing

InSphero’s Akura™ technology platforms team worked with Professor Andreas Hierlemann’s Bioengineering Laboratory at ETH Zürich to develop a microfluidic hanging drop system to assess metabolic competence in developmental toxicity assays.  […]
July 10, 2019

Disruptive 3D Cell Technology Drives Innovative Diabetes R&D at ADA2019

InSphero CEO Jan Lichtenberg reflects on ADA2019 and how InSphero is enabling T1D and T2D Discovery with our 3D InSight™ Diabetes Discovery Platform. Over the past few years, diabetes discovery […]
September 28, 2018

Understanding Microfluidics: the Technology Behind Body-on-a-Chip Systems

Microfluidic chips enable researchers to manipulate, image, and analyze small tissue constructs under optimal culturing conditions. Microfluidics, the technology behind emerging #body-on-a-chip and #organs-on-chips systems, is poised to transform the […]
August 20, 2018

Can 3D in vitro models deliver what pharma needs for NASH and Fibrosis drug discovery?

Pharma companies racing to develop new drugs to combat chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here’s how […]